EPO Part B Claims Reimbursement To Follow Labeling On Dose Reduction
Executive Summary
The Centers for Medicare & Medicaid Services' final policy on Part B reimbursement for Amgen's Aranesp (darbepoetin alfa) and Epogen (epoeitin alfa) in end-stage renal disease follows product labeling recommendations that dosing be reduced when hematocrit levels reach a certain threshold
You may also be interested in...
Amgen EPO Medicare Claims To Be Monitored Via Dose Levels – CMS Draft
Medicare claims for use of Amgen's Aranesp and Epogen in end-stage renal disease will be monitored through blood hematocrit or hemoglobin levels as well as dosage levels, a Centers for Medicare & Medicaid Services' draft policy says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials